Amphera B.V. today announces the positive results of the clinical study with MesoPher in patients with malignant mesothelioma.
Amphera B.V., a spin-off company of Erasmus MC, develops dendritic cell immunotherapies for malignant mesothelioma and other cancers.
Malignant mesothelioma is a fatal cancer caused by inhalation of asbestos fibers. Researchers of Erasmus MC, The Netherlands have developed an innovative immunotherapy for mesothelioma. This new therapy, MesoPher activates the patient’s own immune system against the tumour. MesoPher consists of autologous dendritic cells loaded with allogeneic tumour cell lysate.
Amphera B.V. performed a clinical study with this new approach. Prof Joachim Aerts MD